<DOC>
	<DOCNO>NCT00737711</DOCNO>
	<brief_summary>This single arm study evaluate hemoglobin ( Hb ) increase effect , safety tolerability two-weekly intravenous administration Mircera dialysis patient chronic renal anemia currently treat ESAs . Patients receive intravenous Mircera 0.6 micrograms/kg every 2 week 16 week follow 2 week last treatment visit . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Two-Weekly Intravenous Mircera Treatment Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>male female patient , &gt; =18 year age ; chronic renal anemia ( Hb concentration 8.0g/dL 10.0g/dL ) ; prior erythropoietin stimulate agent ( ESA ) therapy . blood transfusion within previous 4 week ; poorly control hypertension ; significant acute chronic bleeding ; active malignant disease ; congestive heart failure ( NYHA Class IV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>